Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Scientific Officer | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,295 |
Ending reported balance
After 2026-08-13 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-13 · Sale · Disposed 2,007 · Balance 8,051 F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-08-13 · Sale · Disposed 1,556 · Balance 6,495 F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-13 · Sale · Disposed 3,400 · Balance 3,095 F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-13 · Sale · Disposed 800 · Balance 2,295 F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 800 | $119.17 | $95,335.04 |
DisclosureSEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 4 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,295 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,400 | $118.28 | $402,166.62 |
DisclosureSEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 3 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,095 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,556 | $117.08 | $182,170.10 |
DisclosureSEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,495 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,007 | $116.11 | $233,031.37 |
DisclosureSEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,051 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:52 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · derivative · entry 3 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 4,445 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:52 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 2,150 | $110.41 | $237,381.50 |
DisclosureSEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · nonDerivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,058 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:52 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · nonDerivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $98.47 | $0.00 |
DisclosureSEC source: 0001104659-26-015397 · tm266366-2_4seq1.xml · derivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 16,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015397 · tm266366-2_4seq1.xml · derivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,650 Underlying: Common Stock · 16,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 6,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009764 · tm264963-2_4seq1.xml · derivative · entry 3 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,987 Underlying: Common Stock · 6,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 2,026 | $108.99 | $220,813.74 |
DisclosureSEC source: 0001104659-26-009764 · tm264963-2_4seq1.xml · nonDerivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,763 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009764 · tm264963-2_4seq1.xml · nonDerivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 21:12 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6 | $64.60 | $387.60 |
DisclosureSEC source: 0001104659-25-065844 · tm2519881-1_4seq1.xml · nonDerivative · entry 3 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,126 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 21:12 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,313 | $64.81 | $85,095.53 |
DisclosureSEC source: 0001104659-25-065844 · tm2519881-1_4seq1.xml · nonDerivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,132 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:12 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065844 · tm2519881-1_4seq1.xml · derivative · entry 4 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 4,445 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:12 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065844 · tm2519881-1_4seq1.xml · nonDerivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015318 · tm257103-2_4seq1.xml · derivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-13 F3 · derivative.exercise_date: The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after February 14, 2025, such that the option shall be fully vested and exercisable on February 14, 2029. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 26,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015318 · tm257103-2_4seq1.xml · derivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,650 Underlying: Common Stock · 26,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 17,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-078983 · tm2419184-2_4seq1.xml · derivative · entry 2 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,778 Underlying: Common Stock · 17,778 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 53,333 | $0.00 Strike: $43.76 | $0.00 |
DisclosureSEC source: 0001104659-24-078983 · tm2419184-2_4seq1.xml · derivative · entry 1 Garfield Alastair · CIK 0002027261 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,333 Underlying: Common Stock · 53,333 shares Expires 2034-07-07 F1 · derivative.exercise_date: The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after July 1, 2024, such that the option shall be fully vested and exercisable on July 1, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.